Anti-HER2 antibody prolongs overall survival disproportionally more than progression-free survival in HER2-Positive metastatic breast cancer patients
Journal
Breast (Edinburgh, Scotland)
Journal Volume
59
Pages
211
Date Issued
2021-10
Author(s)
Abstract
This meta-analysis aimed to test the hypothesis that the HER2-positive metastatic breast cancer (mBC) patients treated with anti-HER2 antibodies in trial intervention arms have a greater prolongation of overall survival (OS) than of progression-free survival (PFS) and this extra-prolongation of median survival time in OS relates specifically to the anti-HER2 antibody.
Subjects
HER2; Metastatic breast cancer; Overall survival; Progression-free survival
SDGs
Publisher
CHURCHILL LIVINGSTONE
Type
journal article